Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 35 clinical trials
ADCC Mediated B-Cell dEpletion and BAFF-R Blockade (AMBER)

VAY736 dose testing; VAY736 efficacy and safety testing.

adcc
  • 135 views
  • 13 Jul, 2022
  • 43 locations
Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia

The rationale for combining lenalidomide with rituximab derives from preclinical observations suggesting that lenalidomide may enhance the ADCC (antigen-dependent cellular cytotoxicity

chronic lymphocytic leukemia
monoclonal protein
rituximab
lymphoma
monoclonal antibodies
  • 18 views
  • 08 Nov, 2020
  • 1 location
Randomized Trial of Cladribine (CdA) With Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease

antibody dependent cytotoxicity (ADCC or CDC). Patients in complete remission (CR) to cladribine have minimal residual disease (MRD) by immunohistochemistry of the bone marrow biopsy (BMBx IHC), a

  • 46 views
  • 17 Sep, 2022
  • 1 location
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma

This study aims to test if patients achieving a tumor response with the combination of axitinib plus avelumab, can discontinued the axitinib in order to delay the resistance to the anti VEGFR-TKI and decrease the related toxicity of the combination therapy.

  • 0 views
  • 27 Jan, 2021
  • 20 locations
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients (FIL_RENOIR12)

A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy with Rituximab-chemotherapy (R-CHT) for relapsed/refractory FL patients not eligible for autologous transplantation (ASCT)

tumor burden
bendamustine
neutrophil count
rituximab
platelet count
  • 58 views
  • 04 Oct, 2022
  • 28 locations
Pre Operative Trastuzumab in Operable Breast Cancer

overexpress erbB-2. Additionally, trastuzumab is a potent mediator of antibody-dependent cell-mediated cytotoxicity (ADCC). In vitro, trastuzumab-mediated ADCC has been shown to be preferentially exerted on

herceptin
hormone therapy
neutrophil count
growth factor
monoclonal antibodies
  • 71 views
  • 14 May, 2022
  • 1 location
A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (CANFOUR)

This study will evaluate the safety, tolerability, and preliminary antitumor activity of CAN04 both as a monotherapy and in combination with standard of care treatment in subjects with solid cancer tumors. Following completion of the first part, the dose escalation cohorts, and determination of maximum tolerated dose or recommended phase …

pdac
chemotherapy regimen
pembrolizumab
cancer
platinum doublet
  • 244 views
  • 29 Jan, 2022
  • 20 locations
A Phase 1b Dose Escalation Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (RedirecTT-1)

The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R[s]) and schedule for the study treatment (Part 1) and to characterize the safety of the RP2R(s) for the study treatment (Part 2). The RP2R(s) will describe the combination doses and schedules of (tal+tec+dara) the treatment combinations …

human chorionic gonadotropin
carfilzomib
bortezomib
refractory multiple myeloma
lenalidomide
  • 5 views
  • 19 Sep, 2022
  • 13 locations
Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer (BREASTIMMU02)

First preclinical data suggest that pegfilgrastim could constitute a potent adjuvant for immunotherapy with mAb possessing ADCC/ADCP properties as trastuzumab. Combined treatment of

breast cancer
neutrophil count
cancer
trastuzumab
HER2
  • 15 views
  • 23 Mar, 2022
  • 13 locations
Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer

Antibody-dependent cell-mediated cytotoxicity (ADCC) is one of the important mechanisms for suppressing tumors of Trastuzumab. Pre-clinical data suggest that the ADCC effect of Inetetamab, an

metastasis
aromatase inhibitor
erbb2
invasive carcinoma
estrogen receptor
  • 0 views
  • 07 Jul, 2021
  • 1 location